Optimi Health

What Optimi Health does

Optimi Health Corp. (NASDAQ: OPTH; CSE: OPTI) is a commercial-stage Canadian pharmaceutical manufacturer founded in 2020 and headquartered in Princeton, British Columbia. The company produces finished-dose psilocybin and MDMA capsules at a 20,000-square-foot Health Canada Drug Establishment-licensed GMP facility, supplying authorized prescribers and clinical research organizations under regulated access frameworks — primarily Australia's TGA Authorised Prescriber Scheme for treatment-resistant depression and PTSD, with emerging clinical trial supply into Israel and the United Kingdom.

The company's technical platform rests on four pillars: a proprietary library of 200+ mushroom genetics enabling selective cultivar advancement and reportedly achieving approximately 6% psilocybin content extract (the highest-purity botanical psilocybin extract produced to date per company claims); vertically integrated GMP manufacturing with packaging, testing, and international export capability under a single Drug Establishment Licence; a Qualified Person release protocol with HPLC-MS identity and potency testing, USP-grade impurity panels, and validated stability testing per Canadian pharmaceutical regulations; and a controlled chain-of-custody export system with international narcotic export permits issued per shipment. Chief Science Officer Dr. Preston Chase holds multiple awarded and pending patents across catalysis, synthesis, and analytical chemistry.

Optimi Health operates a B2B enterprise sales motion selling pharmaceutical product supply contracts to authorized healthcare providers and clinical research organizations, with pricing negotiated through regulated access frameworks rather than publicly disclosed. The company maintains a five-product portfolio (Natural Psilocybin Extract, MDMA 40mg, MDMA 60mg, Natural Microdose 1mg, and Natural Microdose 2mg) and tracks regulatory access across eight jurisdictions. Following a US$15 million Nasdaq uplisting in May 2026, the company is positioned to scale production, pursue U.S. market entry pending federal rescheduling, and advance an ibogaine development initiative aligned with the April 2026 U.S. Executive Order on psychedelic drug products.

Name

Optimi Health

Legal name

Optimi Health Corp.

Website

https://optimihealth.ca

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Optimi Health Corp. is a commercial-stage Canadian pharmaceutical manufacturer that produces GMP-certified finished-dose psilocybin and MDMA capsules, supplying authorized prescribers and clinical researchers under regulated access frameworks including Australia's TGA Authorized Prescriber Scheme.

Ownership category

akta.pro rank

Product category

Psychedelic Pharmaceuticals Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Psychedelic drug manufacturing
• Pharmaceutical psilocybin capsules
• MDMA drug products
• GMP controlled substances
• Clinical research supply

Headquarters

HQ city

Princeton

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Psychedelic Product Sales: Commercial sale of finished-dose psilocybin and MDMA capsules to authorized prescribers and clinical research organizations under regulated access frameworks. Revenue is generated through product supply contracts with healthcare institutions and pharmacy partners in jurisdictions with authorized psychedelic therapy programs.

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels4 records

Core offering

Optimi Health Corp. manufactures finished-dose GMP pharmaceutical capsules containing naturally derived psilocybin (4-PO-DMT) and synthetic MDMA HCl at a Health Canada Drug Establishment-Licensed facility in British Columbia. The company supplies these products to authorized psychiatrists and clinics in Australia under the TGA Authorized Prescriber Scheme for treatment-resistant depression and PTSD, and to clinical research organizations for controlled studies in Canada, the UK, and other emerging jurisdictions.

Product overview

Optimi Health Corp. is a commercial-stage psychedelic drug manufacturer producing finished-dose psilocybin and MDMA capsules. The company's product portfolio includes Natural Psilocybin Extract (4-PO-DMT) for treatment-resistant depression, MDMA 60mg and 40mg capsules for PTSD, and Natural Microdose products at 1mg and 2mg dosages for microdosing protocols. All products are manufactured at a Health Canada Drug Establishment-licensed GMP facility in British Columbia and supplied to authorized prescribers under Australia's TGA Authorized Prescriber Scheme. The company is structured to scale into additional jurisdictions including the United States upon federal rescheduling.

Differentiator

Problem solved

Functional benefit

Products and services

• Natural Psilocybin Extract Naturally derived psilocybin extract (API 4-PO-DMT) finished-dose capsule manufactured under GMP for supply to authorized prescribers treating treatment-resistant depression under Australia's TGA Authorized Prescriber Scheme.
• MDMA 60 mg Capsule Synthetic MDMA HCl finished-dose capsule at 60mg dosage manufactured under GMP for supply to authorized prescribers and clinical trial sponsors treating post-traumatic stress disorder.
• MDMA 40 mg Capsule Synthetic MDMA HCl finished-dose capsule at 40mg dosage manufactured under GMP for supply to authorized prescribers and clinical trial sponsors treating post-traumatic stress disorder.
• Natural Microdose 1 mg Naturally derived psilocybin (API 4-PO-DMT) microdose capsule at 1mg dosage manufactured under GMP for supply to clinical research organizations and authorized prescribers under microdosing protocols.
• Natural Microdose 2 mg Naturally derived psilocybin (API 4-PO-DMT) microdose capsule at 2mg dosage manufactured under GMP for supply to qualified clinical research organizations conducting controlled microdose studies.

Quantifiable outcome

• No serious adverse events reported among patients treated with psilocybin under Australia's TGA scheme as of December 2025
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• U.S. Federal Government (FDA/ARPA-H)coreStrategic or Co-development Partner · 8 June 2026April 2026 U.S. Executive Order named ibogaine among psychedelic therapies prioritized for accelerated FDA review. $50 million federal allocation through ARPA-H to match state-level psychedelic research investments. FDA Establishment Identifier obtained in 2025.
• Australian National UniversitycoreStrategic or Co-development Partner · 19 February 2026Partnership for national patient registry tracking of treatment outcomes and patient-reported outcomes from MDMA-assisted therapy for PTSD and psilocybin for treatment-resistant depression under Australia's Authorised Prescriber Scheme.
• MAPS Israel / Sheba Medical CentercoreStrategic or Co-development Partner · 26 November 2025Optimi Health supplying GMP MDMA capsules (40mg and 60mg) for MAPS Israel's clinical trial evaluating MDMA-assisted therapy for PTSD in 168 participants. Trial sponsored by Sheba Medical Center with approval from Israeli Ministry of Health.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Compass Pathways: Compass Pathways is developing COMP360, a proprietary synthetic psilocybin formulation for treatment-resistant depression. It is the most direct clinical competitor to Optimi's natural psilocybin product in TRD, targeting overlapping authorized prescriber and clinic channels with a comparable GMP-supplied capsule product.
• Cybin Inc. Cybin is developing CYB003 ( deuterated psilocybin analog) and other psychedelic therapeutics for depression and anxiety. It directly overlaps Optimi's target indications, GMP psychedelic supply model, and publicly listed psychedelic-pharma business model.
• MindMed: MindMed is developing MMED-40 (MDMA) for PTSD and LSD-based therapies. Its MDMA product competes directly with Optimi's MDMA 40mg/60mg capsules for PTSD treatment under regulated access frameworks.
• Filament Health: Filament Health is a Canadian natural psilocybin drug developer and manufacturer, also holding a Health Canada Drug Establishment Licence. It is the closest natural-psilocybin direct competitor to Optimi's botanical psilocybin extract, sharing a similar vertically integrated cultivation-to-capsule model.
• ATAI Life Sciences: ATAI is a clinical-stage biopharmaceutical company developing psychedelic and non-psychedelic therapies for mental health through multiple platform companies. It competes for the same authorized prescriber, clinical trial, and commercial psychedelic supply opportunities as Optimi.
• GH Research: GH Research is developing GH001 (psilocybin via inhalation) for treatment-resistant depression. While delivery mechanism differs, it directly targets the same TRD prescriber channel and competes for clinical and commercial psychedelic supply capacity.

Emerging players

• Numinus Wellness: Numinus operates psychedelic-assisted therapy clinics and provides psilocybin-assisted therapy through Health Canada SAP. It is adjacent rather than directly competitive on drug supply, but its clinic network overlaps Optimi's authorized prescriber go-to-market for psilocybin and MDMA treatments.
• Revive Therapeutics: Revive Therapeutics is developing psilocybin-based therapeutics (including for methamphetamine use disorder) and operates in the same naturally-derived psilocybin category as Optimi, representing a smaller but overlapping competitor in clinical-stage psychedelic development.
• Silo Pharma: Silo Pharma is a developmental-stage psychedelic and CNS-focused biotech with programs in psilocybin and LSD formulations. It overlaps with Optimi in psychedelic development for mental health indications, though at an earlier and smaller scale.

Broad incumbents

• Catalent: Catalent is a large global pharmaceutical CDMO providing oral solid dose manufacturing and controlled-substance capabilities. While not psychedelic-focused, it represents the broad-incumbent pharmaceutical CDMO benchmark relevant to Optimi's GMP manufacturing and finished-dose capsule operations.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/optimihealth

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds6 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Optimi Health